BACKGROUND: After severe trauma, patients develop a norepinephrine-mediated persistent, injury-associated anemia. This anemia is associated with suppression of bone marrow (BM) erythroid colony growth, along with decreased iron levels, and elevated erythropoietin (EPO) levels, which are insufficient to promote effective erythropoiesis. The impact of norepinephrine on iron regulators, such as ferroportin, transferrin, and transferrin receptor-1 (TFR-1), is unknown. Using a clinically relevant rodent model of lung contusion (LC), hemorrhagic shock (HS), and chronic stress (CS), we hypothesize that daily propranolol (BB), a nonselective β blocker, restores BM function and improves iron homeostasis. METHODS: Male Sprague-Dawley rats were subjected to LCHS ± BB and LCHS/CS ± BB. BB was achieved with propranolol (10 mg/kg) daily until the day of sacrifice. Hemoglobin, plasma EPO, plasma hepcidin, BM cellularity and BM erythroid colony growth were assessed. RNA was isolated to measure transferrin, TFR-1 and ferroportin expression. Data are presented as mean ± SD; *p < 0.05 versus untreated counterpart by t test. RESULTS: The addition of CS to LCHS leads to persistent anemia on posttrauma day 7, while the addition of BB improved hemoglobin levels (LCHS/CS: 10.6 ± 0.8 vs. LCHS/CS + BB: 13.9 ± 0.4* g/dL). Daily BB use after LCHS/CS improved BM cellularity, colony-forming units granulocyte, erythrocyte, monocyte megakaryocyte, burst-forming unit erythroid and colony-forming unit erythroid cell colony growth. LCHS/CS + BB significantly reduced plasma EPO levels and increased plasma hepcidin levels on day 7. The addition of CS to LCHS resulted in decreased liver ferroportin expression as well as decreased BM transferrin and TFR-1 expression, thus, blocking iron supply to erythroid cells. However, daily BB after LCHS/CS improved expression of all iron regulators. CONCLUSION: Daily propranolol administration after LCHS/CS restored BM function and improved anemia after severe trauma. In addition, iron regulators are significantly reduced after LCHS/CS, which may contribute to iron restriction after injury. However, daily propranolol administration after LCHS/CS improved iron homeostasis.
BACKGROUND: After severe trauma, patients develop a norepinephrine-mediated persistent, injury-associated anemia. This anemia is associated with suppression of bone marrow (BM) erythroid colony growth, along with decreased iron levels, and elevated erythropoietin (EPO) levels, which are insufficient to promote effective erythropoiesis. The impact of norepinephrine on iron regulators, such as ferroportin, transferrin, and transferrin receptor-1 (TFR-1), is unknown. Using a clinically relevant rodent model of lung contusion (LC), hemorrhagic shock (HS), and chronic stress (CS), we hypothesize that daily propranolol (BB), a nonselective β blocker, restores BM function and improves iron homeostasis. METHODS: Male Sprague-Dawley rats were subjected to LCHS ± BB and LCHS/CS ± BB. BB was achieved with propranolol (10 mg/kg) daily until the day of sacrifice. Hemoglobin, plasma EPO, plasma hepcidin, BM cellularity and BM erythroid colony growth were assessed. RNA was isolated to measure transferrin, TFR-1 and ferroportin expression. Data are presented as mean ± SD; *p < 0.05 versus untreated counterpart by t test. RESULTS: The addition of CS to LCHS leads to persistent anemia on posttrauma day 7, while the addition of BB improved hemoglobin levels (LCHS/CS: 10.6 ± 0.8 vs. LCHS/CS + BB: 13.9 ± 0.4* g/dL). Daily BB use after LCHS/CS improved BM cellularity, colony-forming units granulocyte, erythrocyte, monocyte megakaryocyte, burst-forming unit erythroid and colony-forming unit erythroid cell colony growth. LCHS/CS + BB significantly reduced plasma EPO levels and increased plasma hepcidin levels on day 7. The addition of CS to LCHS resulted in decreased liver ferroportin expression as well as decreased BM transferrin and TFR-1 expression, thus, blocking iron supply to erythroid cells. However, daily BB after LCHS/CS improved expression of all iron regulators. CONCLUSION: Daily propranolol administration after LCHS/CS restored BM function and improved anemia after severe trauma. In addition, iron regulators are significantly reduced after LCHS/CS, which may contribute to iron restriction after injury. However, daily propranolol administration after LCHS/CS improved iron homeostasis.
Authors: Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette Journal: Cell Date: 2006-01-27 Impact factor: 41.582
Authors: Letitia E Bible; Latha V Pasupuleti; Amy V Gore; Ziad C Sifri; Kolenkode B Kannan; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2015-07 Impact factor: 3.313
Authors: Letitia E Bible; Latha V Pasupuleti; Amy V Gore; Ziad C Sifri; Kolenkode B Kannan; Alicia M Mohr Journal: Surgery Date: 2015-07-21 Impact factor: 3.982
Authors: Demet Nalbant; Mohammad Saleh; Frederic D Goldman; John A Widness; Peter Veng-Pedersen Journal: J Pharmacol Exp Ther Date: 2010-01-26 Impact factor: 4.030
Authors: Shirin Hasan; Michael J Mosier; Andrea Szilagyi; Richard L Gamelli; Kuzhali Muthumalaiappan Journal: Surgery Date: 2017-07-14 Impact factor: 3.982
Authors: Getasha D Doobay; Elizabeth S Miller; Camille G Apple; Tyler J Loftus; Kolenkode B Kannan; Philip A Efron; Alicia M Mohr Journal: J Surg Res Date: 2020-12-26 Impact factor: 2.192
Authors: Elizabeth S Miller; Tyler J Loftus; Kolenkode B Kannan; Jessica M Plazas; Philip A Efron; Alicia M Mohr Journal: J Surg Res Date: 2019-06-14 Impact factor: 2.192
Authors: Tyler J Loftus; Kolenkode B Kannan; Christy S Carter; Jessica M Plazas; Juan C Mira; Scott C Brakenridge; Christiaan Leeuwenburgh; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2018-03 Impact factor: 3.313
Authors: Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr Journal: Am J Surg Date: 2020-07-25 Impact factor: 2.565
Authors: Tyler J Loftus; Juan C Mira; Elizabeth S Miller; Kolenkode B Kannan; Jessica M Plazas; Daniel Delitto; Julie A Stortz; Jennifer E Hagen; Hari K Parvataneni; Kalia K Sadasivan; Scott C Brakenridge; Frederick A Moore; Lyle L Moldawer; Philip A Efron; Alicia M Mohr Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Andres R Henriquez; Samantha J Snow; Mette C Schladweiler; Colette N Miller; Janice A Dye; Allen D Ledbetter; Judy E Richards; Kevin Mauge-Lewis; Marie A McGee; Urmila P Kodavanti Journal: Toxicol Appl Pharmacol Date: 2017-12-13 Impact factor: 4.219
Authors: Camille G Apple; Elizabeth S Miller; Tyler J Loftus; Kolenkode B Kannan; Hari K Parvataneni; Jennifer E Hagen; Philip A Efron; Alicia M Mohr Journal: J Surg Res Date: 2019-12-24 Impact factor: 2.192
Authors: Camille G Apple; Elizabeth S Miller; Tyler J Loftus; Kolenkode B Kannan; Chase W Thompson; Maria Cecilia Lopez; Henry V Baker; Lyle L Moldawer; Philip A Efron; Alicia M Mohr Journal: J Am Coll Surg Date: 2019-10-28 Impact factor: 6.113
Authors: Tyler J Loftus; Kolenkode B Kannan; Juan C Mira; Scott C Brakenridge; Philip A Efron; Alicia M Mohr Journal: Shock Date: 2020-10 Impact factor: 3.533